IRCT20200916048733N1 IRCT 2020-10-30 Tabriz University of Medical Sciences The Effect of Alendronate in the Treatment of Osteopenia due to Acute Leukemia The Evaluation of The effects of Alendronates on Osteopenia in Children with Acute Leukemia 2020-03-02 anticipated 30 Complete https://irct.ir/trial/51554 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Prevention. 2 Condition 1: Acute Lymphoblastic Leukemia. Condition 2: Acute Myeloblastic Leukemia. Intervention group: 30 patients with acute leukemia for six months alendronate with the chemical composition of alendronate sodium, tablets with a concentration of 70 mg, with a dose of 35 mg once a week or 5 mg once daily orally, company Hashtgerd Iran Pharmacy will be prescribed.. Yes - There is a plan to make this available What will be shared: All personal data of the study participants can be shared after the individuals are not identified. The study protocol will be published after its completion and the clinical study report will be available. When: The access period will start 6 months after the results are published. To whom: The data will only be available to researchers working in academic and scientific institutions. Conditions: Use of data including demographic characteristics and blood test results and DEXA scan will be allowed in clinical trial and meta-analysis studies. Where to obtain: Laleh Tokhmechian dr.tokhmechian@yahoo.com How to obtain: Personal details including name and surname, place of work, place of study should be provided. Type of study, sample size, study objectives, place of study should also be mentioned. After completing the study and printing the results, the data will be presented as an article. Comments: